Paul Hastings Advised Viking Therapeutics in its $287.5 Million Public Offering of Common Stock
Paul Hastings LLP advised Viking Therapeutics in its underwritten public offering of its common stock with gross proceeds of approximately $287.5 million. Viking intends to use the net proceeds from the offering for continued development of its VK2809, VK2735, AND VK0214 programs and for general research and development, working capital, and general corporate purposes.
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associates Jenna Barba and Kelly Go.
More details on the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.